AstraZeneca

The laboratory AstraZeneca announced Thursday that preliminary data from a trial he conducted with his coronavirus vaccine, Vaxzevria, showed that it generated a increased antibody response against the Omicron variant and others, including Beta, Delta, Alpha, and Gamma, when administered as a third booster dose.

“The increased response was seen in people who were previously vaccinated with Vaxzevria or an mRNA vaccine,” explained the drug manufacturer, adding that it would send this data to regulators around the world given the urgent need for boosters.

AstraZeneca has developed the vaccine with researchers from the Oxford University, and laboratory studies last month found that a three-dose cycle of Vaxzevria was effective against the new, fast-spreading variant, discovered in South Africa in November.

The data is the first published by the company from its booster trials of its vaccine. The company said it adds to “mounting evidence supporting a third dose of its vaccine regardless of the primary vaccination schedule,” Reuters reported.

“These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, greatly increases immunity against coronavirus,” he said. Andrew Pollard, head of the Oxford Vaccine Group, it’s a statement.

A major British trial in December found that the AstraZeneca vaccine increases trials when given as a booster after the initial vaccination with its own vaccine or its own vaccine. Pfizer, based on mRNA technology.

However, the study concluded that mRNA vaccines manufactured by Pfizer and Modern they are the ones that got the most boost to studies when given as booster doses.

Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more